Objectives: The objective of this study was to examine Klebsiella oxytoca clonal and phylogenetic diversity, based on an international collection of carriage isolates non-susceptible to expanded-spectrum cephalosporins (ESCs).
Introduction
Klebsiella oxytoca is an opportunistic pathogen causing nosocomial infections, often in ICU patients or those under immunosuppressive therapy, 1 including bloody diarrhoea after antibiotic treatment. 2 It is naturally resistant to amino-and carboxypenicillins owing to low-level production of chromosomal b-lactamases of the OXY group. 3 -5 Overproduction of these due to promoter-up mutations results in reduced susceptibility or resistance to other b-lactams, such as penicillin -inhibitor combinations, cefuroxime, cefotaxime and aztreonam, and is observed in 10% -20% of clinical isolates. 5 -8 Fevre et al. 9 described six lineages of OXY-type b-lactamases, OXY-1 to -6, that evolved over 100 million years in parallel to housekeeping genes, as OXY gene phylogeny is congruent with the phylogeny based on genes gyrA, rpoB and gapDH.
In addition, K. oxytoca can acquire other enzymes hydrolysing newer-generation b-lactams, like ESBLs, AmpC-type cephalosporinases or carbapenemases, and outbreaks caused by such strains have been reported. 10 -13 The first Klebsiella MLST scheme was introduced for Klebsiella pneumoniae in the mid-2000s, revolutionizing population studies of this pathogen. 14 In May 2014 this scheme, including the rpoB gene used also as a species phylogenetic marker, was adapted to K. oxytoca by Herzog et al., 15 opening the way to similar investigations. The first analysis carried out on isolates mainly from Austria yielded 44 STs. 15 Here, we report a multinational MLST study of K. oxytoca, using isolates that were non-susceptible to expanded-spectrum cephalosporins (ESCs), collected during the EU-funded project MOSAR. 16 The MLST data were compared with PFGE and OXY-type b-lactamase sequences, and supplemented by the profiles of acquired ESC-hydrolysing b-lactamases.
Materials and methods

Study design, clinical isolates and their phenotypic analysis
Between mid-2008 and mid-2011, 17 945 patients in 18 ICUs and rehabilitation units across Europe and Israel were screened for colonization with ESC-resistant Enterobacteriaceae. Rectal swabs were collected at admission, then regularly during hospitalization, and at discharge. The swabs were plated onto Brilliance TM ESBL Agar (Oxoid, Basingstoke, UK); Enterobacteriaceae colonies were identified using the manufacturer's instructions. One colony of each morphotype was collected for definite analysis. Species identification was performed using the Vitek 2 system (bioMérieux, Marcy-l'Étoile, France). All isolates were tested for ESBL and AmpC expression by the ESBL double-disc synergy test (DDST) in the absence and presence of cloxacillin (250 mg/L), 17 and for susceptibility to ertapenem, imipenem and meropenem according to EUCAST (http:// eucast.org). Isolates non-susceptible to at least one carbapenem were subjected to metallo-b-lactamase (MBL), KPC and OXA-48 detection, using DDST with EDTA, 18 the phenylboronic acid disc test 19 and a temocillin disc, 20 respectively.
Typing PFGE was performed as described previously, 21 with the use of the XbaI restriction enzyme (Fermentas, Vilnius, Lithuania). PFGE types and subtypes were discerned according to Tenover et al. 22 Subsequently, electrophoretic patterns were compared by the BioNumerics Fingerprinting software (Version 6.01, Applied Maths, Sint-Martens-Latem, Belgium), using the Dice coefficient and the UPGMA clustering method, with 1% tolerance in band position differences. MLST was carried out according to Herzog et al.; 15 the database available at http://pubmlst.org/koxytoca was used for assigning STs. The relatedness between STs was analysed by eBURST (http://eburst.mlst.net). The clonal diversity index and CIs were calculated according to Grundmann et al. 23 Nucleotide diversity was calculated using DnaSP Ver. 5.10.01. 24 Phylogenetic analysis of nucleotide sequences was performed using Lasergene MegAlign software (DNASTAR Inc., Madison, Wisconsin, USA), using the CLUSTAL W alignment algorithm. Searches of the GenBank database were carried out using the NCBI BLASTn option (www.ncbi.nlm.nih.gov).
Analysis of OXY-type b-lactamases
PCR and sequencing of bla OXY -like genes with promoters were performed as described previously. 9 Amino acid sequences of OXY-type b-lactamases were analysed against the nomenclature database of OXY variants available at http://bigsdb.web.pasteur.fr/klebsiella.
Analysis of acquired b-lactamases
Identification of bla CTX-M -, bla SHV -, bla TEM -, bla DHA -and bla VIM -like genes was done by PCRs and sequencing as reported previously. 25 -28 Nucleotide sequence accession numbers 
Results and discussion
Clonality of the K. oxytoca isolates Sixty-eight ESC-non-susceptible patient-unique K. oxytoca isolates were identified during the MOSAR study. These were recovered in variable numbers (n ¼ 1 -20) in 14 centres from eight countries ( Table 1) . PFGE revealed 61 different patterns clustered into 47 pulsotypes, each characteristic of one centre ( Figure S1 , available as Supplementary data at JAC Online). MLST classified the isolates into 34 STs, of which 24 were new: 137, 141 -144, 147 -163, 165 and 167. PFGE was more discriminatory, splitting six STs into several pulsotypes each, and so being a good tool for K. oxytoca outbreak investigations. The MLST-based clonal diversity index was 94.3% (CI 91.6% -97.0%), reflecting remarkable genetic variety of the isolates. The average nucleotide diversity per MLST gene within the sample, p, ranged from 1.1% to 5.2% (Table S1 ), being similarly high as previously (1.3% -5.9%). 15 Concatemers of the MLST alleles of the 34 STs were subjected to phylogenetic analysis. The phylogenetic tree comprised four lineages of related STs, designated A -D ( Figure 1 and Table S2 ). The lineages A and D dominated, with 17 STs and 23 isolates and 14 STs and 42 isolates, respectively.
Eight STs had more than one isolate (n¼ 42; 61.8%), including five STs present in more than one hospital and country, and split into two to six pulsotypes each (Table 1) . These 'major' STs belonged to the predominant lineages and were: ST9 (n ¼ 9), ST2 (n¼ 8), ST88 (n¼ 6), ST141 (n¼3) and ST36 (n ¼2). Their contribution to larger local K. oxytoca groups varied from the vast majority in the Spanish rehabilitation unit GI (n ¼ 13; 86.7%) to a clear minority in the Latvian ICU RI (n ¼ 4; 20.0%). Twentynine STs were observed in single hospitals, including the most prevalent, ST153 (n¼ 10), which occurred only in Latvia and consisted of a single pulsotype. Ten STs have been identified also in other studies, e.g. ST2 (isolates from Austria and Spain), ST9 (Austria and Germany) and ST36 (Austria) 15 (http://pubmlst.org/ koxytoca).
The eBURST analysis was performed on the entire K. oxytoca MLST database (http://pubmlst.org/koxytoca), containing 161 STs as of 7 May 2015 (Figure 2 ). Of the 34 STs found in this work, 12 were clustered into five eBURST groups of ≥3 STs each ( Table 1 ). The largest one was a clonal complex (CC) with ST2 as the central genotype, distinguished previously and designated as CC2. 15 In the study sample it comprised ST2, ST9, ST141, ST154 and ST155, with 22 isolates (32.4%) from nine hospitals (France, Spain, Portugal, Italy, Latvia and Israel). According to Herzog et al. 15 and the database, CC2 contains six more STs of broad distribution, including Austria, the Netherlands and China. The high prevalence and wide geographical spread of CC2 and its several individual STs may indicate their global character, similar to some CCs and STs of K. pneumoniae, Escherichia coli and Enterobacter cloacae. 29 -33 The four other eBURST groups consisted of three STs each. The first of these included ST4, originally identified in Austria 15 and found here in Latvia, ST5 from Austria 15 and ST161 from Greece in this study. This group, consisting only of ST4 and ST5, was previously defined as 'CC8'. 15 ST144 of an Klebsiella oxytoca clones and b-lactamases 
Klebsiella oxytoca clones and b-lactamases
isolate from Israel was a single-locus variant (SLV) of ST43 and ST108 from Austria, 15 thus forming a distinct group. ST150 from Greece was clustered with ST30 and ST53 from the USA (http:// pubmlst.org/koxytoca). Finally, ST135, ST149 and ST158 from France and Luxembourg formed a group with ST135 at the central position, submitted first from Austria (http://pubmlst.org/ koxytoca). Like other clusters consisting of STs not found in this study (Figure 2 ), these groups may be upgraded to CCs when more clonality data accumulate.
The eBURST results were analysed against the phylogenetic tree of the sample (Figure 1 ) and of the entire K. oxytoca MLST database (data not shown). All STs of one eBURST group were located also in the same lineage. Numbers of polymorphisms in the alleles differentiating all SLVs within CC2 and other groups were low (n ¼ 1 -5; usually 1 -2) in the context of the significant nucleotide diversity within the sample (Tables S1  and S2 ). These results suggest a higher contribution of mutational evolution within eBURST groups, as homologous recombination among distant genotypes could introduce more nucleotide differences.
OXY-like b-lactamases
Of the 22 variants of OXY-like b-lactamases found in the study isolates (Table 1) , 21 enzymes were of four of the six types distinguished previously, namely OXY-1, -2, -4 and -5. 9 The remaining ST165 isolate from Israel had an enzyme that differed remarkably from all those in the database (http://bigsdb.web.pasteur.fr/ klebsiella), and was classified as the first variant of a new type, OXY-7-1 ( Figure S2 ). The most prevalent type was OXY-2, with 12 variants in 42 isolates (61.8%) of 15 STs, followed by OXY-1, with 5 variants in 17 isolates (25.0%) of 12 STs. Apart from OXY-7-1, eight other variants were new. The high contribution of the new variants to the entire database (n¼ 37; as of 7 May 2015) suggests that the actual number of OXY types and variants has been underestimated and that additional diversity will be revealed by analysing more K. oxytoca isolates.
The OXY b-lactamases correlated well with STs; in all cases but one the STs with more than one isolate were homogeneous in OXY variants. The only exception was ST141, which had either OXY-2-7 (in Spain and Portugal) or OXY-2-14 (France), differing by one amino acid substitution. The analysis of the OXY amino acid Figure 1 . Unrooted UPGMA phylogenetic tree of the 34 STs identified in the study, based on concatemers of the MLST loci. The tree was constructed using the Lasergene MegAlign software (DNASTAR Inc.). Only one isolate per ST was included in the dataset. Numbers on the right correspond to STs, followed by variants of OXY b-lactamases detected in individual STs. Lineages are shown on the right. The broken vertical line indicates the cluster cut-off value used, which was 115 nucleotide substitutions per concatemer (3003 bp).
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sequences against the MLST phylogenetic tree of the sample (Figure 1 ) revealed good correlation between OXY types and phylogenetic lineages, with types OXY-1 and OXY-5 corresponding to the lineage A and OXY-4, OXY-7 and OXY-2 being found only in lineages B, C and D, respectively. This observation was consistent with the earlier phylogenetic K. oxytoca studies, based on one to three housekeeping genes and OXY-like b-lactamases. 9, 34, 35 According to the nomenclature used by Fevre et al., 9 our lineages A, B and D corresponded to phylogroups KoI, KoIV and KoII, respectively, whereas lineage C with OXY-7 represents a new branch KoVII, with KoIV as a sister group.
Sequencing of bla OXY gene promoters revealed promoter-up mutations in 27 isolates (38.2%) of 13 STs. Most of these (n¼ 26) had bla OXY-2 -type genes (lineage KoII); the only exception was an isolate with the bla OXY-1 -type gene (KoI) ( Table 1 ). The mutations were common among the 'major' KoII STs, being observed in 8/8 ST2, 6/9 ST9, 1/2 ST36 and 3/3 ST141 isolates. None of the acquired b-lactamase genes tested was identified in 21 of these isolates, suggesting that OXY overproduction was the main mechanism of ESC resistance. 5 -8 Concordantly with previous studies, 7 the mutations occurred in the 210 hexamer, being the G to A transition (at position 5) in 19 isolates or G to T transversion (position 1) in eight isolates. This study confirmed the significant contribution of OXY overexpression to ESC resistance in K. oxytoca, especially in OXY-2 producers. 5 -8 Being the first analysis with the use of MLST, it showed that it may occur in any ST of the OXY-2-producing lineage KoII.
Acquired ESC-hydrolysing b-lactamases
Forty-seven isolates (69.1%) produced acquired ESC-hydrolysing b-lactamases, including 44 ESBL (64.7%) producers, two MBL producers and one AmpC producer ( Two ST137 isolates of different pulsotypes from Spain were the only carbapenem-non-susceptible isolates, produced the MBL VIM-1 and were included in a report on MBL producers from the MOSAR project. 36 Only one ST152 isolate from France had an AmpC-type cephalosporinase DHA-1.
Conclusions
This is the first study, to our knowledge, on ESC-non-susceptible K. oxytoca that combines MLST-based phylogenetic and clonal Klebsiella oxytoca clones and b-lactamases analysis with b-lactamase profiling. It revealed high genetic diversity of the isolates colonizing patients in clinical sites across Europe and Israel. Together with other works 15 (http://pubmlst. org/koxytoca), our study showed a broad international distribution of several STs and clonal clusters, especially CC2, contributing largely to the entire collection. The results were congruent with previous phylogenetic analyses that showed several K. oxytoca clades associated with OXY-like b-lactamase types. 9, 34, 35 A new OXY type, OXY-7, was identified within a distinct lineage. The predominance of two major lineages, KoI (OXY-1/-5) and KoII (OXY-2), was confirmed. 9, 34, 35 Interestingly, organisms of these phylogroups differed remarkably in their main mechanisms of ESC resistance: whereas KoI strains readily acquired ESBLs and rarely overexpressed OXYs, the KoII ones were mainly OXY hyperproducers and carried ESBLs less frequently. Further studies on the ecology and microbiology of K. oxytoca lineages are necessary to verify and explain this observation, especially because this study had several limitations associated with the MOSAR study design regarding the isolates' collection. The isolates were recovered from rectal carriage only and from hospitalized patients only, and were preselected based on their non-susceptibility to ESCs. These limitations must be considered while interpreting the data presented, mainly those on the occurrence and distribution of individual clones.
